ArticleFrontiers in immunology2025
PRR enhances anti-tumor immunity and suppresses colitis by promoting the development and survival of naive T and iNKT cells.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The (pro)renin receptor (PRR) is a multifunctional transmembrane protein that enhances β-catenin/TCF1 signaling and V-ATPase-mediated lysosomal acidification. Emerging evidence indicates that it may also regulate potential roles in regulating T cell development, survival, and immune responses. Here, we demonstrated that PRR promotes the maturation and survival of T cells within the thymus. In particular, PRR-deficient mice exhibited a significant reduction in iNKT cells in the thymus and periphery. PRR promoted the energy synthesis process in mitochondria, as evidenced by increased mitochondrial amount and membrane potential. This phenomenon was accompanied by an increase in TCF1 expression and lysosomal acidification. Furthermore, PRR enhanced the survival of naive T and iNKT cells in the periphery, while simultaneously suppressing inflammatory cytokine-producing T cells, thereby preventing colitis. In contrast, PRR enhanced resistance against tumor growth by increasing the number of tumor-infiltrating Th1 and iNKT cells, which in turn promoted NK cell recruitment. This study indicates that PRR is critical for supporting T cell maintenance, suppressing excessive inflammation, and enhancing anti-tumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.